Considerations for Biosimilars, Unbranded Biologics, and Originator Biologics

Definitions of originator biologics, biosimilars, and unbranded biologics, including their lifespan in the marketplace.

A glance at the process and regulations of switching, plus how an interchangeability study is conducted.

The role of evidence-based recommendations around biosimilars and unbranded biologics to increase patient care, plus how payers and providers evaluate biosimilars through clinical data across multiple indications.

Savings and incentives associated with the utilization of biosimilars and unbranded biologics, including a look at how it impacts formulary access.

How an open marketplace impacts future competition, pricing transparency, and formulary management.

An overview of how benefit channels, such as pharmacy benefit and medical benefit, differ and how it impacts utilization of biosimilars and unbranded biologics.

Challenges with biosimilars and unbranded biologics are discussed and how can they be improved.

Discussion on how payers and providers collaborate to enhance patient care and cost management. The upcoming entry of biosimilars post-2023 and their potential influence is also covered.